Incyte Corp. (INCY)

Schlusskurs vom Vortag:

$51.18

Offen:

$50.99

24-Stunden-Volumen:

1.55M

Marktkapitalisierung:

$11.60B

Einnahmen:

$3.70B

Nettoeinkommen (Verlust:

$597.60M

KGV:

27.34

EPS:

1.89

Netto-Cashflow:

$449.00M

1W Leistung:

-1.28%

1M Leistung:

-8.61%

6M Leistung:

-4.77%

1J Leistung:

-29.72%

1-Tages-Spanne:

$50.87

$51.85

52-Wochen-Spanne:

$50.27

$75.74

Incyte Corp. Stock (INCY) Company Profile

Firmenname

Incyte Corp.

Sektor

Healthcare (1191)

Branche

Biotechnology (688)

Telefon

302-498-6700

Adresse

1801 Augustine Cut-Off, Wilmington, DE

Mitarbeiter

1,208

Twitter

@Incyte

Nächster Verdiensttermin

2024-04-30

Neueste SEC-Einreichungen

INCY's Discussions on Twitter

Incyte Corp. Stock (INCY) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-02-14	Herabstufung	JMP Securities	Mkt Outperform → Mkt Perform
2023-12-13	Hochstufung	Leerink Partners	Market Perform → Outperform
2023-12-04	Hochstufung	Guggenheim	Neutral → Buy
2023-11-21	Herabstufung	Goldman	Buy → Neutral
2023-07-25	Eingeleitet	Citigroup	Buy
2023-05-04	Herabstufung	BofA Securities	Buy → Neutral
2023-04-10	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2023-03-24	Hochstufung	SVB Securities	Underperform → Market Perform
2023-01-31	Eingeleitet	Piper Sandler	Overweight
2022-08-03	Herabstufung	Evercore ISI	Outperform → In-line
2022-08-03	Herabstufung	Guggenheim	Buy → Neutral
2022-07-28	Eingeleitet	Wells Fargo	Equal Weight
2022-02-09	Herabstufung	SVB Leerink	Mkt Perform → Underperform
2022-01-18	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2021-11-19	Eingeleitet	BMO Capital Markets	Market Perform
2021-07-20	Hochstufung	The Benchmark Company	Hold → Buy
2021-02-10	Herabstufung	SVB Leerink	Mkt Perform → Underperform
2021-01-07	Eingeleitet	Truist	Buy
2021-01-04	Hochstufung	Guggenheim	Neutral → Buy
2020-06-16	Eingeleitet	The Benchmark Company	Hold
2020-05-06	Herabstufung	JP Morgan	Overweight → Neutral
2020-04-29	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2020-04-01	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2020-03-24	Fortgesetzt	William Blair	Outperform
2020-03-13	Hochstufung	BofA/Merrill	Neutral → Buy
2020-02-04	Fortgesetzt	BofA/Merrill	Neutral
2020-01-03	Bestätigt	BMO Capital Markets	Market Perform
2020-01-03	Herabstufung	Mizuho	Buy → Neutral
2020-01-02	Herabstufung	Guggenheim	Buy → Neutral
2019-10-03	Eingeleitet	Mizuho	Buy
2019-09-12	Eingeleitet	BMO Capital Markets	Market Perform
2019-09-05	Hochstufung	JMP Securities	Mkt Perform → Mkt Outperform
2019-09-05	Fortgesetzt	Morgan Stanley	Equal-Weight
2019-09-05	Hochstufung	Oppenheimer	Perform → Outperform
2019-05-21	Eingeleitet	Credit Suisse	Neutral
2019-05-03	Herabstufung	Barclays	Overweight → Equal Weight
2019-04-11	Eingeleitet	Stifel	Hold
2019-04-03	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2019-01-24	Hochstufung	William Blair	Mkt Perform → Outperform

Alle ansehen

Incyte Corp. Aktie (INCY) Neueste Nachrichten

The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals

Zacks Investment Research

Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX

Zacks Investment Research

Allogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: Should You Buy?

Zacks Investment Research

Incyte Should Consider Significant Stock Buyback And Prioritize R&D, Analyst Recommends

Benzinga

Peeling Back The Layers: Exploring Incyte Through Analyst Insights

Benzinga

Incyte (INCY) Earnings Expected to Grow: Should You Buy?

Zacks Investment Research

Finanzdaten der Incyte Corp.-Aktie (INCY)

Incyte Corp. (INCY) Umsatz 2024

Incyte Corp. (INCY) Nettogewinn 2024

Incyte Corp. (INCY) Free Cashflow 2024

Incyte Corp. (INCY) Gewinn je Aktie 2024